Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
UX-001SA-ER (NPC-09, UX001)
Also known as: UX-001
print preview
bookmark
share with colleague
General Information
Company
Ultragenyx Pharmaceutical Inc.
Description
Extended-release oral formulation of sialic acid
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase II
Indication
Muscular atrophy
Partner
Nobelpharma Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information